TLSI

Business Context and Reporting Period

Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: TriSalus is an oncology-focused medical technology company developing the Pressure-Enabled Drug Delivery (PEDD) platform to improve therapeutic delivery to solid tumors. Its primary commercial product is the TriNav Infusion System, used for liver cancer treatments (TARE/TACE). The company is also developing nelitolimod, an investigational immunotherapeutic, in Phase 1 clinical trials.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 53.4% to $45.2 million, driven by a significant increase in TriNav unit sales.
• Expense Management: Research and Development (R&D) expenses decreased 15.4% to $15.0 million, primarily due to the close-out of clinical trial expenses for nelitolimod. Conversely, Sales and Marketing expenses rose 11.1% due to performance-based compensation, and General and Administrative (G&A) expenses increased 19.4% due to accelerated stock-based compensation and professional fees.
• Debt Financing: The company borrowed an additional $10.0 million under the First Delayed Draw Term Loan in February 2025 after meeting revenue thresholds, increasing total debt obligations.
• Non-Cash Items: The company recorded a $2.7 million loss on the change in fair value of the contingent earnout liability, compared to an $11.2 million gain in 2024.

Guidance, Outlook, and Risks

• Clinical Outlook: Phase 1 dose escalation trials for nelitolimod in locally advanced pancreatic cancer (LA-PDAC) have completed enrollment. Data is expected in early 2026. The company intends to seek a pharmaceutical partner for Phase 2 development rather than self-funding.
• Commercial Expansion: TriNav received a second permanent HCPCS code (C8004) in April 2025 for mapping procedures. The company launched new devices (TriNav FLX and TriNav XP) to expand into non-malignant applications like uterine and thyroid embolization.
• Liquidity and Capital: As of December 31, 2025, cash balances were $20.4 million. The company raised approximately $42.6 million in net proceeds from a public offering in February 2026 (subsequent to year-end). Management anticipates continuing losses and the need for additional capital to fund operations and development.
• Key Risks:
  • Internal Controls: Management identified a material weakness in internal control over financial reporting related to accounting for significant transactions, which remained unremediated as of December 31, 2025.
  • Reimbursement: Continued market adoption depends on maintaining favorable reimbursement rates from CMS and private payors.
  • Debt Covenants: The company must maintain a minimum cash balance of $5.0 million (reduced from $10.0 million in November 2025) and meet revenue thresholds to avoid triggering repayment obligations on its OrbiMed Credit Agreement.

Investor Verification Checklist

• Internal Control Remediation: Verify the timeline and progress for remediating the material weakness in accounting for significant transactions.
• Cash Runway: Assess the sufficiency of the $20.4 million year-end cash balance plus the $42.6 million subsequent offering proceeds against projected operating losses and debt service obligations.
• Debt Covenants: Monitor compliance with the OrbiMed Credit Agreement revenue thresholds and minimum cash covenants to avoid acceleration of debt.
• Partnership Strategy: Track progress in securing a pharmaceutical partner for nelitolimod Phase 2 trials, as self-funding is not the current plan.
• Reimbursement Stability: Confirm that the new HCPCS codes (C9797 and C8004) are sustaining expected reimbursement rates and adoption rates for new device applications.